Stada Arz says first six months of 2018 as expected

10 August 2018

German generics major Stada Arzneimittel (SAZ: Xetra), which just last week announced it is increasing its presence in the important biosimilar sector by taking a majority stake in an affiliate Bioceuticals Arzneimittel, today released mixed financial results for the first half of 2018.

Stada noted that reported group sales dipped 1% in the first six months to 1,137.5 million euros ($1.32 billion). Sales of STADA Vietnam JV are no longer included. Adjusted for or portfolio and currency effects, sales increased by 5% to 1,171.6 million euros.

Reported earnings before interest, taxes, depreciation and amortization (EBITDA) were up 18% in the reporting period to 260.6 million euros, while adjusted EBITDA rose by 10% to 261.7 million euros. Reported net income leapt 83% to 165.3 million euros, while adjusted net income rose 31% to 149.7 million euros.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK